(Q47269531)

English

"True" weight-based dosing versus "flat" dosing of ribavirin: will the WIN-R please come forward?

scientific article published in October 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

0 references

"True" weight-based dosing versus "flat" dosing of ribavirin: will the WIN-R please come forward? (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

1 reference

based on heuristic

inferred from title

author name string

Jason Smith

1

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

Steven-Huy B Han

2

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

language of work or name

0 references

publication date

1 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

46

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

4

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

953-956

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of ribavirin in patients with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C in African Americans: summary of a workshop

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

An infectious molecular clone of a Japanese genotype 1b hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Viral kinetics in hepatitis C virus: special patient populations

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21890

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.21890

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17886337

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47269531&oldid=1458536163"